![Can recombinant technology address asparaginase Erwinia chrysanthemi shortages? - Maese - 2021 - Pediatric Blood & Cancer - Wiley Online Library Can recombinant technology address asparaginase Erwinia chrysanthemi shortages? - Maese - 2021 - Pediatric Blood & Cancer - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/7488d868-f580-4890-af63-5ad5511abd23/pbc29169-fig-0001-m.jpg)
Can recombinant technology address asparaginase Erwinia chrysanthemi shortages? - Maese - 2021 - Pediatric Blood & Cancer - Wiley Online Library
![PEG-asparaginase Less Toxic Than L-asparaginase for Pediatric Acute Lymphoblastic Leukemia - Cancer Therapy Advisor PEG-asparaginase Less Toxic Than L-asparaginase for Pediatric Acute Lymphoblastic Leukemia - Cancer Therapy Advisor](https://www.cancertherapyadvisor.com/wp-content/uploads/sites/12/2018/12/pediatriccancerpatientrisk_864835.jpg)
PEG-asparaginase Less Toxic Than L-asparaginase for Pediatric Acute Lymphoblastic Leukemia - Cancer Therapy Advisor
![Efficacy and safety of PEG-asparaginase versus E. coli L-asparaginase in Chinese children with acute lymphoblastic leukemia: A meta-analysis - Authorea Efficacy and safety of PEG-asparaginase versus E. coli L-asparaginase in Chinese children with acute lymphoblastic leukemia: A meta-analysis - Authorea](https://authorea.com/users/337798/articles/463360-efficacy-and-safety-of-peg-asparaginase-versus-e-coli-l-asparaginase-in-chinese-children-with-acute-lymphoblastic-leukemia-a-meta-analysis/master/file/figures/FIGURE%201%20Flowchart%20of%20the%20study%20selection/FIGURE%201%20Flowchart%20of%20the%20study%20selection.png?1593445111)
Efficacy and safety of PEG-asparaginase versus E. coli L-asparaginase in Chinese children with acute lymphoblastic leukemia: A meta-analysis - Authorea
![Cancers | Free Full-Text | Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy Cancers | Free Full-Text | Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy](https://www.mdpi.com/cancers/cancers-14-00902/article_deploy/html/images/cancers-14-00902-g001.png)
Cancers | Free Full-Text | Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy
![Frontiers | Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles Frontiers | Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles](https://www.frontiersin.org/files/Articles/418731/fbioe-06-00212-HTML/image_m/fbioe-06-00212-g003.jpg)
Frontiers | Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles
![PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review | Semantic Scholar PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/849b889bc07b5787bd57dc7e062bd2b1ef5692f1/6-Table2-1.png)
PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review | Semantic Scholar
![Algorithm for treatment with PEG-asparaginase (* = mean number of vials). | Download Scientific Diagram Algorithm for treatment with PEG-asparaginase (* = mean number of vials). | Download Scientific Diagram](https://www.researchgate.net/publication/293200044/figure/fig2/AS:530815080767488@1503567585632/Algorithm-for-treatment-with-PEG-asparaginase-mean-number-of-vials.png)
Algorithm for treatment with PEG-asparaginase (* = mean number of vials). | Download Scientific Diagram
![Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial - The Lancet Oncology Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/782e544c-75e2-4f5b-95b6-e601f786d1e5/gr2_lrg.gif)
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial - The Lancet Oncology
![Hypersensitivity Rates in Pediatric Patients Receiving Intravenous or Intramuscular Asparaginase Agents Hypersensitivity Rates in Pediatric Patients Receiving Intravenous or Intramuscular Asparaginase Agents](https://jhoponline.com/images/jhop/2020/Vol10-No1-Feb/hyper_table1.png)
Hypersensitivity Rates in Pediatric Patients Receiving Intravenous or Intramuscular Asparaginase Agents
![Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial - The Lancet Oncology Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/af3441eb-1d2e-43bc-a2cb-dcf5991147b8/gr1_lrg.jpg)
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial - The Lancet Oncology
![Frontiers | Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles Frontiers | Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles](https://www.frontiersin.org/files/Articles/418731/fbioe-06-00212-HTML/image_m/fbioe-06-00212-g004.jpg)
Frontiers | Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles
![Noncovalent PEGylation of l-Asparaginase Using PEGylated Polyelectrolyte - Journal of Pharmaceutical Sciences Noncovalent PEGylation of l-Asparaginase Using PEGylated Polyelectrolyte - Journal of Pharmaceutical Sciences](https://jpharmsci.org/cms/attachment/2061608477/2063121716/gr1.jpg)
Noncovalent PEGylation of l-Asparaginase Using PEGylated Polyelectrolyte - Journal of Pharmaceutical Sciences
![Frontiers | Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles Frontiers | Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles](https://www.frontiersin.org/files/Articles/418731/fbioe-06-00212-HTML/image_m/fbioe-06-00212-t002.jpg)
Frontiers | Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles
Insights into the Distribution and Functional Properties of l-Asparaginase in the Archaeal Domain and Characterization of Picrophilus torridus Asparaginase Belonging to the Novel Family Asp2like1 | ACS Omega
![Recent developments in l-asparaginase discovery and its potential as anticancer agent - ScienceDirect Recent developments in l-asparaginase discovery and its potential as anticancer agent - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1040842815000037-gr1.jpg)
Recent developments in l-asparaginase discovery and its potential as anticancer agent - ScienceDirect
![The coagulopathy and thrombotic risk associated with L-Asparaginase treatment in adults with acute lymphoblastic leukaemia | Leukemia The coagulopathy and thrombotic risk associated with L-Asparaginase treatment in adults with acute lymphoblastic leukaemia | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fleu.2012.290/MediaObjects/41375_2013_Article_BFleu2012290_Fig1_HTML.gif)
The coagulopathy and thrombotic risk associated with L-Asparaginase treatment in adults with acute lymphoblastic leukaemia | Leukemia
![l-Asparaginase In Situ Encapsulated into Zwitterionic Nanocapsules with a Prolonged Half-Life | ACS Applied Polymer Materials l-Asparaginase In Situ Encapsulated into Zwitterionic Nanocapsules with a Prolonged Half-Life | ACS Applied Polymer Materials](https://pubs.acs.org/cms/10.1021/acsapm.2c00068/asset/images/large/ap2c00068_0008.jpeg)
l-Asparaginase In Situ Encapsulated into Zwitterionic Nanocapsules with a Prolonged Half-Life | ACS Applied Polymer Materials
![Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study | Scientific Reports Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fsrep39463/MediaObjects/41598_2016_Article_BFsrep39463_Fig2_HTML.jpg)